Salud financiera de hoja de balance de Aurobindo Pharma
Salud financiera controles de criterios 6/6
Aurobindo Pharma tiene un patrimonio de accionistas total de ₹281.9B y una deuda total de ₹66.5B, lo que sitúa su ratio deuda-patrimonio en 23.6%. Sus activos y pasivos totales son ₹439.2B y ₹157.3B respectivamente. El BAIT de Aurobindo Pharma es de ₹36.8B, por lo que su ratio de cobertura de intereses es de 38.4. Tiene efectivo e inversiones a corto plazo que ascienden a ₹71.5B.
Información clave
23.6%
Ratio deuda-patrimonio
₹66.49b
Deuda
| Ratio de cobertura de intereses | 38.4x |
| Efectivo | ₹71.49b |
| Patrimonio | ₹281.95b |
| Total pasivo | ₹157.29b |
| Activos totales | ₹439.24b |
Actualizaciones recientes sobre salud financiera
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Recent updates
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50
Feb 11Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 08These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Nov 10Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet
Aug 19Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹235.6B) de AUROPHARMA superan a sus pasivos a corto plazo (₹130.1B).
Pasivo a largo plazo: Los activos a corto plazo de AUROPHARMA (₹235.6B) superan a sus pasivos a largo plazo (₹27.2B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AUROPHARMA tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de AUROPHARMA ha pasado de 42.7% a 23.6% en los últimos 5 años.
Cobertura de la deuda: La deuda de AUROPHARMA está bien cubierta por el flujo de caja operativo (30%).
Cobertura de intereses: Los pagos de intereses de la deuda de AUROPHARMA están bien cubiertos por el BAIT (38.4x cobertura).